Nautilus Biotechnology (NAUT) Accumulated Expenses (2020 - 2026)

Nautilus Biotechnology has reported Accumulated Expenses for 7 years, with the latest figure at $3.6 million in Q2 2026.

• Quarterly Accumulated Expenses rose 20.93% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 million (up 20.93% YoY) and the FY2025 annual result came in at $3.2 million, up 24.69% from the prior year.
• Accumulated Expenses improved to $3.6 million in Q2 2026 per NAUT's latest filing, from $3.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $4.3 million in Q3 2023 and troughed at $2.5 million in Q4 2024.
• A 5-year average of $3.4 million and a median of $3.4 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 136.17% in 2022, then plunged 35.41% in 2024.
• Over 5 years, Accumulated Expenses stood at $3.5 million in 2022, then advanced by 11.82% to $3.9 million in 2023, then slumped by 35.41% to $2.5 million in 2024, then increased by 24.69% to $3.2 million in 2025, then climbed by 11.84% to $3.6 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.6 million, $3.3 million, and $3.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.